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for grading of ‘canonical oligodendrogliomas’ should be 
adapted, how pediatric oligodendrogliomas (known to lack 
codeletions) should be defined, which platforms and cut-off 
levels should ideally be used for demonstration of particu-
lar molecular aberrations, and how the diagnosis of oligo-
dendroglioma should be made in centers/countries where 
molecular diagnostics is not available. Meanwhile, smart 
integration of morphological and molecular information 
will lead to recognition of biologically much more uniform 
groups within the spectrum of diffuse gliomas and thereby 
facilitate tailored treatments for individual patients.
Keywords Oligodendroglioma · Mixed glioma · 
Glioblastoma · Histopathology · 1p/19q loss ·  
Molecular marker
Introduction
For over a century, classification of neoplasms has been 
based on their microscopic characteristics and the histo-
pathological diagnosis has provided the cornerstone for 
therapeutic decision-making. The ‘taxonomy’ of tumors of 
the central nervous system (CNS) in the most recent, i.e., 
2007 World Health Organization (WHO) classification of 
these neoplasms is still largely based on their histopatho-
logical features as well [73]. Diffuse gliomas are by far the 
most frequent neoplasms originating from the CNS paren-
chyma itself. The common denominator of this heterogene-
ous group of neoplasms is extensive, infiltrative growth of 
individual tumor cells and/or groups of these cells (‘diffuse 
growth’) into the neuropil, i.e., the dense network of neu-
ronal and glial processes of the CNS parenchyma [23].
Over 75 % of the diffuse gliomas in adult patients are 
astrocytic, about two-thirds of these being represented by 
Abstract For nearly a century, the diagnosis and grad-
ing of oligodendrogliomas and oligoastrocytomas has been 
based on histopathology alone. Roughly 20 years ago, the 
first glioma-associated molecular signature was found with 
complete chromosome 1p and 19q codeletion being particu-
larly common in histologically classic oligodendrogliomas. 
Subsequently, this codeletion appeared to not only carry 
diagnostic, but also prognostic and predictive information, 
the latter aspect only recently resolved after carefully con-
structed clinical trials with very long follow-up times. More 
recently described biomarkers, including the non-balanced 
translocation leading to 1p/19q codeletion, promoter hyper-
methylation of the MGMT gene, mutations of the IDH1 or 
IDH2 gene, and mutations of FUBP1 (on 1p) or CIC (on 
19q), have greatly enhanced our understanding of oligo-
dendroglioma biology, although their diagnostic, prognos-
tic, and predictive roles are less clear. It has therefore been 
suggested that complete 1p/19q codeletion be required for 
the diagnosis of ‘canonical oligodendroglioma’. This tran-
sition to an integrated morphological and molecular diag-
nosis may result in the disappearance of oligoastrocytoma 
as an entity, but brings new challenges as well. For instance 
it needs to be sorted out how (histopathological) criteria 
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the most malignant form, glioblastoma. Oligodendroglio-
mas and oligoastrocytomas have been generally grouped 
together as oligodendroglial tumors and account for less 
than 10 % of the diffuse gliomas (Fig. 1). Of note, in chil-
dren, glioma variants with a more circumscribed growth 
pattern are more frequent than diffuse gliomas, and oli-
godendroglial tumors are rare (<4 % of the primary CNS 
tumors) [85]. According to the WHO 2007 classification, 
after typing a diffuse glioma as astrocytic, oligodendro-
glial, or mixed, these neoplasms are graded as WHO grade 
II/low grade, WHO grade III/anaplastic or WHO grade IV/
glioblastoma (WHO grade I being reserved for more cir-
cumscribed gliomas, such as pilocytic astrocytoma). Micro-
scopic features used for grading are the presence/absence 
of marked mitotic activity, florid microvascular prolifera-
tion (MVP, i.e., marked hypertrophy and hyperplasia of 
endothelial cells and pericytes resulting in a multilayered 
aspect of the microvessel walls), and necrosis [73]. Une-
quivocal histological typing and grading of diffuse gliomas 
is challenging however, especially because the biological 
diversity of these tumors is difficult to capture in precise 
microscopic criteria. Also, the samples provided for histo-
pathological analysis are not always (fully) representative. 
This results in a high rate of interobserver variation in the 
diagnosis of diffuse gliomas, including oligodendroglial 
tumors [36, 65, 117].
For the past 20 years, the knowledge on the genetic/
molecular underpinnings of gliomagenesis is rapidly 
expanding. It is now fully clear that certain molecular 
aberrations carry important diagnostic, prognostic and/or 
predictive information because they provide clinically rel-
evant information on tumor type, biological behavior, and/
or expected response to a particular treatment regimen, 
respectively. It is therefore to be expected that (like, e.g., 
Fig. 1  Relative frequency of 
histopathologically diagnosed 
oligodendroglial and oligoas-
trocytic tumors in the spectrum 
of glial tumors of the CNS: a 
in 95,564 patients of all age 
groups; b in 10,274 children 
and adolescents (0–19 years). 
Information extracted from 
CBTRUS statistical report: 
NPCR and SEER, 2007–2011 
[85]
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sarcomas and hematological malignancies) classification 
of CNS tumors will increasingly be based on the presence 
of particular molecular aberrations, and oligodendroglial 
tumors are amongst the first in line for such a change.
In this review, we reconstruct the transition from a 
purely morphological to an integrated morphological and 
molecular scheme for classification of the heterogeneous 
group of oligodendroglial tumors. After summarizing clini-
cal, radiological and histopathological aspects of these neo-
plasms (‘Setting the stage’), the molecular underpinnings 
of oligodendroglial tumors and the diagnostic, prognostic 
and/or predictive value of these aberrations will be dis-
cussed (‘Molecular mechanisms and markers’). In the last 
part of this article (‘WHO’s next?’), we elaborate on how 
these markers can be used to reclassify oligodendroglial 
tumors more objectively, but with some challenges and 
unanswered questions remaining. For a review on similar 
aspects concerning diffuse astrocytomas, glioblastomas, 
and pilocytic astrocytomas the reader is referred to com-
panion articles in the present cluster.
Setting the stage
Gliomas originate from neural stem cells or glial progeni-
tor cells that develop or maintain glial characteristics [136]. 
According to the WHO 2007 classification, based on the 
resemblance of the tumor cells with non-neoplastic glial 
cells most diffuse gliomas can be typed as astrocytic, oli-
godendroglial, or mixed (i.e., oligoastrocytoma) [73]. Oli-
godendroglial tumors most commonly arise in the frontal 
lobe, somewhat more frequently in males and with the peak 
incidence in the 5th and 6th decade. Robust enhancement 
is not a common feature in low-grade examples and sug-
gests transformation to a higher histologic grade [61, 73]. 
Most oligodendroglioma patients present with seizures. 
Patients experiencing generalized tonic–clonic seizures 
were reported to more often have the greatest lesion load 
in mesial frontal regions, including cortex connected to the 
genu of the corpus callosum, while in patients with partial 
seizures, the oligodendrogliomas were located more caudo-
laterally in orbitofrontal and temporal lobes but typically 
sparing cortex connected to the genu, indicating that the 
genu of the corpus callosum is a major pathway for seizure 
generalization [130].
Because of their locally aggressive behavior and the 
fact that they cannot be cured by current therapies, diffuse 
gliomas are considered one of the most devastating can-
cers [23]. Progress has been made with oligodendroglioma 
patients such that current standard of care (surgery, radio-
therapy and chemotherapy) yields median survival times 
of 12–14 years even in WHO grade III examples. Patients 
with a WHO grade II oligodendroglioma may survive even 
longer, but sooner or later such tumors generally progress 
to a high-grade malignant glioma as well. Given the often 
young age at presentation, however, this patient category 
still substantially contributes to the high average number of 
‘years of life lost’ for patients suffering from a CNS tumor 
[17]. Rarely, extracranial metastases of oligodendroglial 
tumors occur (for recent reviews, see [71, 78]). Only a tiny 
fraction of oligodendroglial tumors is thought to be due to 
single-gene hereditary syndromes such as biallelic Lynch 
syndrome [37, 42].
As originally described by Bailey and Bucy [7], nuclear 
features are key for microscopic recognition of an oligo-
dendroglial phenotype, although some architectural growth 
patterns also provide useful clues (Fig. 2). In low-grade oli-
godendrogliomas, the nuclei are generally round and uni-
form with crisp nuclear membranes, delicate chromatin and 
small-to-inconspicuous nucleoli. In anaplastic examples, 
cells are frequently enlarged and epithelioid with nuclei 
that often show increased size and pleomorphism, a more 
vesicular chromatin pattern and more prominent nucleoli, 
but the tumor still maintains an overall sense of regularity 
and nuclear roundness [80, 81]. The clear, perinuclear halo 
that often is seen in oligodendroglial tumor cells is in fact 
an artifact of formalin fixation, which is typically absent in 
frozen sections and rapidly fixed specimens. The combina-
tion of the round nuclei and perinuclear haloes results in 
a fried-egg appearance of individual cells and in a honey-
comb architectural pattern of groups of evenly spaced cells.
Oligodendroglial tumors are often highly cellular 
lesions in central regions with closely packed, relatively 
small cells. However, in less cellular areas at the tumor 
periphery, the diffuse infiltrative growth is easily appreci-
ated, often with prominent secondary structure formation, 
such as clustering of tumor cells around the perikarya of 
preexistent neurons (satellitosis), under the pial surface 
(subpial aggregation), and surrounding cortical small ves-
sels (perivascular aggregates). The presence of a branching 
network of delicate capillaries (chicken-wire pattern) and 
extensive calcification are common, but not specific addi-
tional features in oligodendrogliomas. Rare oligodendro-
glial tumors show marked pleomorphism (‘polymorphic 
oligodendroglioma’) or cells arranged in a rhythmic/spon-
gioblastic fashion. Furthermore, part of the tumor cells in 
oligodendrogliomas may show a gliofibrillary or minigemi-
stocytic phenotype with strong staining for glial fibrillary 
acidic protein (GFAP) of the cytoplasm, or rarely even sig-
net-ring cell morphology [68, 69, 89]. Typically, oligoden-
drogliomas in children are histologically similar, but may 
involve unusual sites such as the posterior fossa and the 
spinal cord more frequently and lack the molecular back-
ground of adult counterparts [102]. Occasionally, a mostly 
pediatric, slowly progressive oligodendroglial-like prolif-
eration presents as a diffuse leptomeningeal neoplasm [97, 
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Fig. 2  Common histopathologic patterns encountered in classic (IDH 
mutant, 1p19q codeleted) oligodendrogliomas include: a a honey-
comb-like arrangement of evenly spaced tumor cells with uniformly 
rounded nuclei and clear haloes imparting a “fried egg” appearance; 
additionally, there are branching capillaries (arrow) resembling 
chicken-wire; b mucin-filled microcystic spaces; c, d minigemisto-
cytes with small rounded bellies of eosinophilic cytoplasm and clas-
sic nuclear cytology including rounded countours, delicate “salt and 
pepper” chromatin, sharp nuclear membranes, and small nucleoli (c 
intra-operative smear; d tissue section); e foci of anaplastic transfor-
mation with increased cellularity and enlarged cell size (left) in com-
parison to the low-grade precursor cells (right). Anaplastic examples 
often feature: f enlarged epithelioid cells with increased pleomor-
phism, vesicular chromatin, macronucleoli, but a maintained general 
sense of nuclear roundness; g increased mitotic index and occasional 
“red crunchy” cells with brightly eosinophilic lysosomal inclusions 
(arrow); h microvascular proliferation; and i foci of tumor necrosis, 
more often consisting of collections of apoptotic cells rather than the 
pattern of pseudopalisading necrosis seen in glioblastomas. Immu-
nohistochemically, some cases are completely GFAP negative, with 
only reactive astrocytes staining (j), while others (k) show strong 
expression in gliofibrillary oligodendrocytes (perinuclear rim and var-
iable tadpole-like tail) or minigemistocytes (not shown). l A stain for 
neurofilament protein often highlights the infiltrative growth pattern 
by showing entrapped neurons and axons. m Tumoral synaptophysin 
positivity is not uncommon and can include a paranuclear dot-like 
pattern. n A stain for IDH1-R132H mutant protein highlights peri-
neuronal satellitosis in this positive tumor with cortical involvement. 
Unlike diffuse astrocytomas, most oligodendrogliomas show only 
limited p53 immunoreactivity (o) and retained ATRX expression (p)
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100]. The latter may include the 1p19q codeletion pattern 
of adult oligodendroglioma, but more frequently harbors 1p 
deletion without 19q loss [79, 101].
Histopathological typing of diffuse gliomas is rela-
tively straightforward for tumors at the ‘prototypic ends’. 
However, there is a surprisingly wide morphological spec-
trum that includes both common and diagnostically mis-
leading patterns (Figs. 2, 3). As indicated by their name, the 
histopathological diagnosis of oligoastrocytomas is based 
on the presence of neoplastic glial cells with morphological 
Fig. 3  Less common and sometimes diagnostically confusing his-
topathologic patterns encountered in classic (IDH mutant, 1p19q 
codeleted) oligodendrogliomas include: a–e a lobulated or nodular 
growth pattern can simulate a neuroendocrine tumor, with immu-
nohistochemical pitfalls including CD56 (b) and synaptophysin (c) 
positivity; however, demonstration of IDH1 R132H mutant protein 
(d) and 1p19q codeletion confirmed the diagnosis in this case; e focal 
spindled cytology was also encountered, simulating a more astrocy-
toma-like pattern. Rare examples demonstrate more overt neuronal 
differentiation, including neurocytic (f) and ganglioglioma-like (g, h). 
Neurocytic foci often feature slightly smaller and more hyperchro-
matic nuclei surrounding central collections of delicate pink neuropil 
(i.e., neurocytic rosettes). In contrast, the case with ganglioglioma-
like maturation featured areas of classic anaplastic oligodendroglioma 
(g note also the “red crunchy” cells); FISH studies (not shown) 
revealed 1p19q codeletions not only in this component, but in neo-
plastic ganglion cells (h) as well
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characteristics of both astrocytes and oligodendrocytes. 
These cells may be diffusely mixed or separated, although 
the latter form is rare [73]. The diagnostic definitions of 
oligoastrocytomas have been subjective and their diagno-
sis is poorly reproducible. In fact, conceptual preferences 
of individual (neuro)pathologists further impact cell type 
determinations. For instance, those who readily accept the 
existence of mixed gliomas are likely to more liberally 
diagnose oligoastrocytomas than those skeptical that this 
entity exists (Fig. 4a) [16, 35].
While in the past, different systems for the assessment of 
malignancy grade of oligodendroglial tumors were applied 
[67], the WHO classification has since gained world-wide 
acceptance [60, 73]. According to the WHO criteria, an oli-
godendroglioma without necrosis, florid MVP, or marked 
mitotic activity is considered as WHO grade II, while the 
presence of one or more of these features generally war-
rants an anaplastic designation (WHO grade III). Neverthe-
less, considerable problems arise in daily practice given the 
subjectivities of these definitions. For instance, how many 
mitoses are needed for “marked mitotic activity”? One 
study reported that finding six or more mitoses per ten high 
power fields allowed for recognition of oligodendrogliomas 
with more aggressive (WHO grade III) clinical behavior 
[36]. Additional challenges arise because the grading cri-
teria for astrocytomas differ and as such, the initial deter-
mination of astrocytoma versus oligodendroglioma is often 
critical to whether the same glioma will be considered low- 
or high-grade.
In oligodendrogliomas, florid MVP and necrosis do 
not have the same unfavorable connotation as in diffuse 
astrocytic neoplasms, and such tumors are still considered 
WHO grade III. In mixed gliomas, the presence of florid 
MVP was similarly considered to be consistent with WHO 
grade III, whereas prior to the 2007 WHO classification, 
the significance of necrosis was unclear. In a large study 
published in 2006, necrosis was found to be a statistically 
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Fig. 4  Diffuse gliomas: from histopathologically to molecularly 
defined entities. Diffuse gliomas histopathologically form a spectrum, 
both with regard to cell type (astrocytic, oligodendroglial, mixed) 
and malignancy grade. Especially, delineation of oligoastrocytomas 
from (more) pure astrocytic and oligodendroglial tumors is poorly 
reproducible. In practice, (neuro)pathologists who readily accept the 
existence of mixed gliomas will more liberally diagnose oligoastro-
cytomas, while those who are skeptical that this entity exists will 
designate the vast majority of diffuse gliomas as either astrocytic 
or oligodendroglial (a). Introducing 1p/19q codeletion as a defining 
feature for oligodendrogliomas will in most cases allow for a clear 
distinction from astrocytic neoplasms and can be expected to drasti-
cally reduce the fraction of neoplasms diagnosed as mixed/oligoas-
trocytic (b). Meanwhile, especially in children, CNS tumors resem-
bling classic oligodendrogliomas often lack 1p/19q codeletion; the 
best position for these ‘pediatric oligodendrogliomas’ in an improved 
taxonomy of CNS tumors requires further study. c Molecular markers 
helpful in daily clinical practice for state-of-the-art classification of 
diffuse gliomas. A recently published algorithm proposes immunohis-
tochemistry (IHC) as a first step, allowing for correct classification of 
esp. the IDH1 R132H mutant protein positive, ATRX negative (and 
thus ATRX mutated) astrocytomas [96]. Ideally, in other tumors, sub-
sequent molecular testing for 1p/19q codeletion status and/or other 
IDH1 and IDH2 mutations is performed. Variable testing for other 
markers can be helpful as well: in IDH mutated (mut) diffuse glio-
mas demonstration of TERT mutation indicates oligodendroglioma 
and of TP53 mutation astrocytoma; demonstration of TERT mutation 
in IDH wild type (wt) diffuse gliomas as well as of EGFR amplifi-
cation/EGFRvIII strongly indicates high-grade malignant astrocytic 
tumor/glioblastoma; a KIAA-BRAF fusion gene is typically found in 
pilocytic astrocytoma, while mutations in the histone genes H3F3A, 
HIST1H3B/C indicate pediatric type high-grade gliomas (which may 
also harbor ATRX mutations and show loss of ATRX immunoreac-
tivity). A, O, OA low-grade astrocytoma, oligodendroglioma, oligoas-
trocytic/mixed glioma, resp.; AA, AO, AOA anaplastic astrocytoma, 
oligodendroglioma, oligoastrocytic/mixed glioma, resp.; GBM glio-
blastoma, GBM-O glioblastoma with oligodendroglial component. 
See also text in this article and the other reviews in this cluster
▸
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significant predictor of poor overall survival for patients 
with anaplastic oligoastrocytoma, but not for those with 
anaplastic oligodendroglioma [80]. Others published simi-
lar observations [107, 119], leading to the conclusion that 
for anaplastic oligoastrocytomas, stratification into grade 
III and IV on the basis of absence or presence of necro-
sis was justified leading to a ‘glioblastoma with oligoden-
droglial component’ (GBM-O) category in the WHO 2007 
classification [73]. Of note, the concept of GBM-O had 
already been around for more than a decade [24].
More recently, Appin et al. [4] reported that GBM-Os 
tend to arise in younger patients, more frequently originate 
from lower grade precursors and are associated with longer 
survival. The better prognosis of patients with GBM-O com-
pared to those with classic glioblastoma in this series may 
then at least partly be explained by the fact that these GBM-
Os were more often secondary glioblastomas with IDH 
mutation occurring in younger patients with dedifferenti-
ated tumors [56], a clinical and molecular subtype already 
known for a better prognosis. Other studies on GBM-O pro-
vided conflicting results (see for review [29]). For example, 
of 339 glioblastoma cases included in the EORTC_26981/
NCIC_CE.3 trial and originally diagnosed as glioblastoma 
by a local pathologist, 15 % was reclassified as GBM-O 
but this re-grouping lacked prognostic significance [44]. 
Acknowledging that histopathological distinction of GBM-O 
from small cell glioblastoma can be difficult, it is likely that 
the latter variant was overrepresented in some studies tak-
ing glioblastomas as a starting point, particularly given their 
reportedly high frequencies of EGFR gene amplification. 
These data once again illustrate the fact that histopathologi-
cal discrimination of mixed gliomas from pure counterparts 
remains subjective and at least partly explain differences in 
overall survival of patients with anaplastic oligoastrocytomas 
between various large prospective studies.
Not infrequently, other primary CNS tumors may 
show oligodendroglioma-like features including fried-egg 
appearance of (part of) the tumor cells. Examples are glial 
neoplasms like pilocytic astrocytoma and clear cell epend-
ymoma, as well as neuronal or glioneuronal tumors such as 
neurocytomas and dysembryoplastic neuroepithelial tumors 
(DNTs). The presence of Rosenthal fibers and eosinophilic 
granular bodies in a glial tumor suggests pilocytic astro-
cytoma, although they can be rarely found in diffuse glio-
mas as well. Other features that are helpful in this respect 
include biphasic growth pattern (pilocytic astrocytomas), 
the formation of true rosettes or perivascular pseudorosettes 
(ependymal tumors) and the formation of specific glioneu-
ronal elements (DNT). Furthermore, immunohistochemical 
studies (e.g., dot-like staining for epithelial membrane anti-
gen typically present in ependymal tumors) and occasion-
ally electron microscopy (for ultrastructural demonstration 
of ependymal or neuronal differentiation) may be helpful 
in problematic cases. However, synaptophysin staining (for 
quite some time considered as sound evidence for neuronal 
rather than glial differentiation) has been described to occur 
in ‘bona fide’ oligodendrogliomas (and other gliomas) as 
well, indicating that the progenitor cells from which these 
tumors are derived are less strictly committed to glial lin-
eage than previously thought [92, 123]. This may also 
explain that occasionally oligodendrogliomas are reported 
to display neurocytic or ganglioglioma-like maturation and 
that differentiation from other, more typical glioneuronal 
tumors can be challenging [91, 114, 115].
Unequivocal recognition of oligodendrogliomas is hin-
dered by the lack of specific immunohistochemical markers 
for these tumors [89]. More recently described candidate 
markers in this respect are Olig2 (a murine bHLH transcrip-
tion factor expressed in neural progenitors and oligoden-
droglia and considered to be essential for oligodendrocyte 
development) and the neuronal intermediate filament alpha 
internexin (INA). After initial optimism, Olig2 expression 
was not found helpful for distinguishing oligodendroglio-
mas from diffuse astrocytomas, nor from DNTs or pilocytic 
astrocytomas (although lack of Olig2 staining may aid in 
the diagnosis of neurocytoma or clear cell ependymoma 
rather than oligodendroglioma) [56, 72, 86, 93, 113]. Simi-
larly, INA expression did not appear to provide the sensi-
tivity and specificity needed for robust recognition of oli-
godendrogliomas [14, 26, 27]. Very recently, expression of 
phosphorylated cyclic-AMP responsive element binding 
protein (p-CREB, a transcription factor involved in gliom-
agenesis) was described to be present in astrocytomas but 
largely absent in prototypic oligodendrogliomas [8], but the 
sensitivity for identifying 1p19q codeleted oligodendro-
gliomas was only 70 % and the value of this tool for dis-
crimination of diffuse gliomas awaits further elucidation.
While multiple studies show that distinctive histologic 
features in diffuse gliomas are associated with clinical out-
come and with specific molecular alterations, the lack of 
robust histopathological criteria causes substantial diagnos-
tic interobserver variability, even among experienced neu-
ropathologists [36, 65]. This situation results in undesirable 
clinical discrepancies [117]. More precise classification 
of gliomas is urgently needed for adequate assessment of 
prognosis and appropriate planning of treatment. While 
improved definitions of morphological features may be 
helpful in this respect [64], a more promising approach is 
to integrate molecular data in order to create a more objec-
tive and reproducible glioma classification.
Molecular mechanisms and markers
Like other neoplasms, diffuse gliomas develop as a result 
of genetic and molecular alterations that further accumulate 
816 Acta Neuropathol (2015) 129:809–827
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with tumor progression. These aberrations allow the tumor 
to acquire assets for sustained survival and growth and to 
escape normal growth restraining influences [39, 40]. Some 
of these molecular abnormalities carry important diag-
nostic, prognostic and/or predictive information, giving 
support for a major molecular component in future tumor 
characterization. The most promising markers for oligoden-
droglial tumors are briefly discussed below.
Complete 1p/19q codeletion
In 1994, using restriction fragment length polymorphism 
analysis, Reifenberger et al. [95] reported for the first 
time that many oligodendroglial tumors show loss of het-
erozygosity (LOH) for chromosome arms 1p and 19q. 
Further studies have shown that 1p/19q loss in fact results 
from a non-balanced translocation t (1:19) (q10:p10) with 
subsequent loss of one of the derivative chromosomes 
[38, 48]. This explains why it is the loss of the entire arms 
of 1p and 19q that is related to clinical outcome, rather 
than smaller terminal or interstitial deletions which occur 
by a completely different mechanism and are occasion-
ally encountered in astrocytic tumors, such as glioblas-
toma [47]. Recently, by using genome-wide, 50 base pair 
single-end sequencing, 1p/19q codeletion was demon-
strated to be the only copy number aberration that was 
stable across spatial regions of low-grade diffuse gliomas 
and their recurrences [122]. Virtually all 1p/19q codeleted 
tumors have a pro-neural expression profile, supporting 
the hypothesis that these gliomas originate from a bi-
potential progenitor cell able to give rise to neurons and 
oligodendrocytes [25].
The high clinical relevance of 1p/19q loss became clear 
when this marker appeared to be associated with sensitivity 
to chemotherapy and improved outcome. Cairncross et al. 
[19] were the first to point out that recurrent anaplastic oli-
godendrogliomas with 1p/19q codeletion were far more 
responsive to PCV (procarbazine–ccnu–vincristine) chem-
otherapy, with virtually all tumors responding. In large 
prospective randomized studies on diffuse glioma, 1p/19q 
codeletion was associated with improved overall survival 
but also with increased benefit of adjuvant PCV chemother-
apy given after radiotherapy [18, 118, 127].
Application of ‘strict’ (as opposed to ‘relaxed’) histo-
pathological criteria for recognition of oligodendroglio-
mas results in a higher correlation with 1p/19q codeleted 
tumors [2, 51]. In a large series of ‘classic’ glioblastomas, 
2–8 % of the primary/de novo and 0–13 % of secondary 
tumors were reported to show 1p/19q codeletion [83]. In 
some studies, GBM-Os showed a similar low frequency of 
1p/19q codeletion [44], while others reported an increased 
frequency of codeletions in GBM-Os compared to conven-
tional glioblastoma [4].
IHD1/IDH2 mutations
Following the initial discovery of isocitrate dehydroge-
nase (IDH) gene mutations in a small subset of especially 
younger glioblastoma patients with prolonged survival, a 
high percentage (70–80 %) of IDH1 and IDH2 mutations 
were identified in diffuse grade II and III gliomas, regard-
less of astrocytic or oligodendroglial cell type. Nearly all 
mutations involve codon 132 of IDH1 or the homologous 
codon 172 of IDH2, with c.395G>A (p.R132H) represent-
ing >90 % of all IDH1 mutations [87, 135]. The IDH1 
R132H mutant protein can be detected reliably using 
immunohistochemistry [21]. This will, however, miss 
approximately 10 % of IDH mutations. The IDH mutation 
rate in 1p/19q codeleted tumors approaches 100 % [96, 
124]. Further studies have shown that IDH mutation is an 
early event in gliomagenesis (‘driver mutation’), and likely 
precedes the development of the 1p/19q codeletion, the lat-
ter possibly specifically driving a diffuse glioma towards 
the classic oligodendroglioma morphologic phenotype, 
whereas superimposed TP53 and ATRX mutations drive it 
towards the astrocytoma phenotype instead [3, 124, 125].
Through an altered substrate specificity, IDH mutations 
give rise to metabolic alterations, including an increase in 
production of 2-hydroxyglutarate (2-HG) which can inhibit 
histone demethylation and induces a glioma hypermethyla-
tion phenotype (glioma CpG island methylated phenotype 
or G-CIMP) [45, 75, 116]. In turn, this leads to a variety 
of downstream chromatin remodeling and transcriptional 
alterations. IDH status has major prognostic implications 
for patients with diffuse gliomas, and was suggested to be 
a better predictive factor for benefit to chemotherapy in the 
RTOG trial on adjuvant PCV chemotherapy in anaplastic 
oligodendroglial tumors [20]. IDH mutant tumors without 
1p/19q codeletion have a worse outcome compared to IDH 
mutant, 1p/19q codeleted grade III tumors, but better than 
grade II and III tumors without IDH mutations.
MGMT promoter methylation and G‑CIMP
O6-alkylguanine-DNA-alkyltransferase (AGT), encoded by 
the O6-methylguanine-DNA-methyltransferase (MGMT) 
gene, is a key repair enzyme that removes alkyl and methyl 
adducts from DNA, making cells with functional enzyme 
less sensitive to alkylating and methylating chemotherapy 
than those incapable of repairing these adducts. Indeed, 
gliomas with MGMT promoter methylation were demon-
strated to be more sensitive to the alkylating agent temozo-
lomide (TMZ) [43]. The biomarker value of immunohisto-
chemistry for the repair enzyme itself is less clear [50, 94]. 
Later on, methylation of very specific regions in the MGMT 
promoter was found to be highly correlated to MGMT 
expression [6, 77].
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Several studies have shown a high rate of MGMT pro-
moter methylation in grade II and III gliomas, which 
subsequently was demonstrated to be related to IDH 
mutational status and G-CIMP. These findings at least 
partly explain the favorable outcome of MGMT methyl-
ated tumors after not only chemotherapy or combined 
chemoradiotherapy, but also after radiotherapy only [120, 
127]. Genome-wide methylation studies have shown 
that MGMT promoter methylation is usually part of the 
G-CIMP phenotype, but about 10 % of G-CIMP positive 
tumors lack IDH mutation [82]. Virtually all 1p/19q code-
leted oligodendrogliomas show G-CIMP and MGMT pro-
moter methylation. With the Illumina 450 HM beadchip, 
a specific epigenetic pattern for IDH mutated and 1p/19q 
codeleted tumors can be identified [6, 121, 132]. With 
combined analysis of IDH, MGMT and G-CIMP status, it 
has become clear that the prognostic role of MGMT sta-
tus in grade III tumors is related to IDH mutated tumors, 
whereas MGMT methylation status is predictive for ben-
efit to alkylating chemotherapy in the absence of IDH 
mutations in both grade III and IV gliomas (i.e., high-
grade astrocytomas) [121, 128, 132]. In EORTC study 
26951 on anaplastic oligodendroglial tumors the methyla-
tion of specific regions in the MGMT promoter was found 
to be the strongest predictive factor for benefit to PCV 
chemotherapy [121].
CIC and FUBP1 mutations
Several other mutations have been identified in 1p/19q 
codeleted tumors. These include inactivating mutations 
in the homolog of the Drosophila capicua (CIC) and far-
upstream binding protein 1 (FUBP1) gene, considered to 
occur secondary to the unbalanced translocation and found 
to be present in ~50–70 % and 15–30 % of 1p/19q code-
leted tumors, respectively. These genes are located on the 
19q (CIC) and 1p (FUBP1) chromosomal arms, support-
ing their putative roles as tumor suppressor genes [10]. No 
CIC mutations were identified in tumors without 19q loss 
[103]. The higher rate of CIC mutations in pure oligoden-
drogliomas suggests CIC mutations may be related to the 
phenotypic characteristics of these tumors [10, 54]. CIC 
mutations occur almost invariably with IDH mutations, 
and they are exceedingly rare in other brain tumors. CIC is 
a downstream component of receptor kinase (RTK) path-
ways (RTK–RAS–RAF–MAPK) and blocks transcription 
through binding to a regulatory region. It is negatively reg-
ulated by RTK signaling which blocks the function of CIC 
through MAPK-mediated phosphorylation. This results in 
the degradation of CIC. FUBP1 mutations may result in 
MYC activation or ribosome biogenesis. The additional 
impact of these alterations on the outcome of patients with 
1p/19q codeleted glioma is presently unclear.
TERT and ATRX
Two mutually exclusive mutations play a role in telomere 
maintenance in gliomas: telomerase reverse transcriptase 
(TERT) mutations in hot spot promoter regions C228T, 
C250T result in increased expression of telomerase. Para-
doxically, these mutations are present in both 1p/19q code-
leted oligodendrogliomas and in IDH wild type high-grade 
gliomas [5, 59]. Virtually all 1p/19q codeleted tumors carry 
TERT mutations. Gliomas with TERT mutations in the 
presence of 1p/19q codeletion (i.e., oligodendrogliomas), 
have a very favorable outcome where the same TERT muta-
tions in the absence of this codeletion or IDH mutations 
herald a grim prognosis (comparable to glioblastoma) [70]. 
TERT mutations are mutually exclusive with ATRX (alpha 
thalassemia mental retardation syndrome X linked) muta-
tions, which are instead seen in the majority of WHO grade 
II-III astrocytomas and secondary glioblastomas. Critical 
for normal telomere homeostasis, these mutations are asso-
ciated with the alternative lengthening of telomeres (ALT) 
phenotype, IDH and TP53 mutations, but not with 1p/19q 
loss [58, 62, 96, 104, 131]. Most diffuse gliomas thus show 
either ATRX or TERT mutations. The mechanisms involved 
in escaping senescence in the remaining set of gliomas still 
await further elucidation.
EGFR and chromosome 7
EGFR amplifications are virtually mutually exclusive with 
1p/19q codeletion and with IDH mutations [52]. This sug-
gests that these tumors follow a different oncogenic route 
from the start. The presence of polysomy of chromosome 
7 and amplification of the epidermal growth factor recep-
tor (EGFR) gene is associated with TERT mutations and a 
prognosis similar to primary glioblastoma in general. The 
presence of EGFR amplification in histologically pure ana-
plastic oligodendrogliomas is indicative of glioblastoma 
[31]. The small cell variant of glioblastoma has morpholog-
ical similarities to anaplastic oligodendroglioma but carries 
EGFR amplification in 70 % of cases [90].
Anaplastic oligodendrogliomas
Anaplastic oligodendroglial tumors usually have addi-
tional genetic aberrations, in particular 9p LOH and/or 
deletion of the CDKN2A gene (p16), PIK3CA mutations, 
and polysomies [10, 11, 13, 31]. Recent data of The Can-
cer Genome Atlas (TCGA) consortium on lower grade 
(WHO grade II and III) gliomas show that IDH mutations 
in these gliomas are virtually mutually exclusive with 
homozygous deletion of CDKN2A and with amplification 
of EGFR [1, 12]. As discussed above, EGFR amplification 
mainly occurs in 1p/19q intact, IDH wild type gliomas and 
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indicates the diagnosis glioblastoma. Some studies sug-
gested shortened recurrence free survival times or poorer 
prognosis for oligodendroglial tumors with polysomy of 
1p and 19q, but the exact importance of this finding is not 
yet clear [108, 129].
Pediatric oligodendroglial tumors
Pediatric and some young adulthood oligodendrogliomas 
are different from oligodendrogliomas in adults in that 
they show neither IDH mutations nor combined 1p/19q 
codeletion and thus represent a different disease [21, 63, 
102, 111]. The rare childhood examples with IDH muta-
tions and 1p19q codeletions almost always occur in ado-
lescents, suggesting that they indeed carry the adult type 
of oligodendroglioma. In a similar vein, some young adult 
patients with tumors resembling oligodendroglioma, but 
lacking IDH mutations and 1p/19q codeletion may har-
bor the pediatric type of oligodendroglioma. This is sim-
ilar to many other pediatric neoplasms that resemble an 
adult counterpart, but differ genetically and biologically 
[34, 110]. Given that it is difficult to define entities by a 
lack of findings, an objective definition for pediatric oli-
godendroglioma will likely remain a challenge until these 
tumors are better characterized at the molecular level. 
Recently, disseminated oligodendroglioma-like leptome-
ningeal neoplasms (an entity that predominantly affects 
children) were reported to frequently harbor concurrent 
BRAF-KIAA1549 gene fusions and 1p deletion, generally 
without 19q deletion [101].
Intratumoral genetic heterogeneity
In a recent study sequencing the exomes of 23 low-grade 
gliomas and their recurrences, in 43 % of cases, at least 
half of the mutations in the initial tumor were undetected 
at recurrence, including mutations considered to be driver 
mutations such as TP53 and ATRX. These findings sug-
gest that recurrent tumors are often seeded by cells derived 
from the initial tumor at a very early stage of their evolu-
tion [55]. Indeed, other groups reported substantial intratu-
moral genetic heterogeneity (ITGH) in diffuse gliomas [88, 
109, 122]. Adequate understanding of the consequences of 
such ITGH for the diagnosis and treatment of these tumors 
needs further study. Moreover, particular (chemo) therapeu-
tic strategies/compounds may elicit certain molecular aber-
rations in tumor cells. In the study of Johnson et al. [55], 
tumors from 6 of 10 patients treated with the temozolomide 
(TMZ) were hypermutated and harbored driver mutations 
in the RB (retinoblastoma) and Akt-mTOR (mammalian 
target of rapamycin) pathways, thereby bearing the signa-
ture of TMZ-induced mutagenesis.
Who’s next?
The distinct differences in outcome of the various molecu-
larly defined subsets even within morphologically similar 
types and grades of diffuse gliomas summarized above is 
now ready to be translated into a refined, more objective 
glioma classification with associated clinical, prognostic, 
and predictive implications. In fact, schemes were already 
proposed for a classification that is based on assessment of 
molecular aberrations rather than purely on histopathology 
[126]. Based on the available data, ‘canonical oligodendro-
glioma’ in adult patients could be defined as a diffuse gli-
oma with complete 1p/19q codeletion, most of which will 
also have an IDH and a TERT mutation (Fig. 4b). Indeed, 
these tumors have the best outcome in the group of diffuse 
gliomas and show increased sensitivity to adjuvant PCV 
chemotherapy. Of note, 1p/19q status is most likely not the 
ultimate identifier of sensitivity to adjuvant (PCV) chem-
otherapy, better candidate markers being IDH mutation, 
G-CIMP and MGMT promoter methylation.
The question then arises how to call tumors with clear 
discrepancy between morphology and molecular informa-
tion. Diffuse gliomas with intact 1p/19q may have oligo-
dendroglial phenotype, but have a less favorable outcome 
especially if no IDH mutation is present. Vice versa, in 
many larger series on glioma a limited number of tumors 
diagnosed as low grade or anaplastic astrocytoma (5–10 %) 
has combined 1p/19q loss, most of these are IDH mutated. 
Several studies have now demonstrated that the molecu-
lar classification corresponds better with outcome than 
histopathology.
Recently, a group of neuropathologists with ample 
expertise in histopathological and molecular diagnosis of 
CNS tumors reached consensus and formulated the Inter-
national Society of Neuropathology-Haarlem consensus 
guidelines (ISN-Haarlem guidelines) on how molecular 
information could be incorporated into an updated version 
of the WHO classification. Salient recommendations of 
this group included that: (1) diagnostic entities should be 
defined as narrowly as possible to optimize interobserver 
reproducibility, clinicopathological predictions and thera-
peutic planning; (2) diagnoses should be ‘layered’ with 
histologic classification, WHO grade, and molecular infor-
mation listed below an ‘integrated diagnosis’ (Table 1); (3) 
determinations should be made for each tumor entity as 
to whether molecular information is required, suggested 
or not needed for its definition; (4) some pediatric enti-
ties should be separated from their adult counterparts [74]. 
The layered diagnostic format allows to leave the ‘molec-
ular layer’ empty and to state in the integrated diagnosis 
that molecular testing was not performed. However, with 
the present status of molecular knowledge it is clear that 
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molecular information is required for optimal diagnosis of 
diffuse gliomas and that in this context for most cases an 
‘empty molecular layer’ must be viewed as shortcoming.
For molecular subtyping of diffuse gliomas several 
markers may be exploited (Fig. 4c). Elaborating on the sug-
gestions in the ISN-Haarlem guidelines, a recent study on 
adult diffuse low- and high-grade gliomas demonstrated 
that the integrated morphological and molecular diagno-
sis (incorporating information on ATRX, IDH and 1p/19q 
codeletion) had significantly greater prognostic power for 
overall and progression-free survival than the original, his-
topathological diagnosis. Acknowledging that ATRX muta-
tions in IDH mutant diffuse gliomas almost never co-occur 
with 1p/19q codeletions and result in loss of immunohis-
tochemical ATRX staining of tumor cell nuclei, an algo-
rithm was proposed for a stepwise diagnostic approach that 
could reduce the number of molecular analyses needed for 
a final diagnosis: initial immunohistochemistry for ATRX 
and IDH1 R132H mutant protein, when necessary (e.g., 
in case of positive ATRX staining of tumor cell nuclei and 
negative staining for IDH1 R132H) followed by 1p/19q 
analysis and subsequently by IDH sequencing [96]. Alter-
natively, assessment of TERT and/or TP53 mutations may 
be exploited for establishing such a prognostic classifica-
tion, canonical oligodendrogliomas typically being TERT 
mutated and TP53 wild type (Fig. 4c). Immunohistochem-
istry for p53 protein (strong staining of a large percentage 
of tumor cell nuclei) has been reported as a highly specific, 
but moderately sensitive surrogate marker for the presence 
of a TP53 mutation in gliomas [112].
Several studies have now revealed that molecular and 
epigenetic/methylation characteristics allow reclassifica-
tion of oligoastrocytomas or morphologically ambiguous 
diffuse gliomas into either oligodendroglioma or astrocy-
toma. Based on these conclusions, some authors suggest 
that it is time to say farewell to oligoastrocytoma as an 
entity [104, 133]. Indeed, the diagnosis of mixed gliomas 
has suffered amongst the greatest levels of discordance, 
even among expert neuropathologists. Already in 1997 
the finding that low-grade oligoastrocytomas generally 
have either 1p/19q codeletion or TP53 mutation made the 
authors question the presence of truly mixed gliomas [76]. 
GBM-O is in fact nothing more than the grade IV variant 
of oligoastrocytoma and all of the caveats discussed above 
pertain. Distinct molecular subsets can easily be carved out 
of the GBM-O category and placed into more clinically 
uniform subtypes, such as primary/IDH wild type glioblas-
tomas, secondary/IDH mutated glioblastomas, and 1p/19q 
codeleted anaplastic oligodendrogliomas. With the adop-
tion of an integrated morphological and molecular diag-
nosis from a clinical perspective, the need for a separate 
mixed diffuse glioma (incl. GBM-O) category will largely 
disappear [32, 41, 53, 83].
The suggestion that it is time to say farewell to oligoas-
trocytoma as a diagnosis immediately elicited case reports 
of tumors showing molecular features of composite oligo-
dendroglioma and astrocytoma [46, 134]. Evidently, while 
molecular classification allows for more stringent definition 
of the vast majority of diffuse gliomas, there will always be 
single cases that do not readily fit into the scheme. Further 
investigations are required to sort out if such ‘outliers’ jus-
tify the creation of separate diagnostic categories [105].
Introducing a new, integrated morphological and 
molecular definition of subgroups of diffuse gliomas will 
in itself already lead to a change in WHO grade in some 
cases (see Figs. 5, 6 for examples). Also, evaluation of the 
Table 1  Layered format for integrated morphological and molecular diagnosis of CNS tumors as proposed in ISN-Haarlem guidelines [74]
Example 1 and 2 are further illustrated in Figs. 5 and 6, respectively
IHC immunohistochemistry, FISH fluorescent in situ hybridization
Layer 1, integrated diagnosis: integrating all ‘highlights’ from tissue-based information as described in layers 2–4; until molecular information 
becomes available, this can be filled out initially as ‘pending’
 Example 1: anaplastic oligodendroglioma (WHO grade III); 1p/19q codeleted
 Example 2: low-grade astrocytoma (WHO grade II); IDH-mut, ATRX loss
Layer 2, histological classification: standard microscopic diagnosis
 Example 1: glioblastoma with oligodendroglial component
 Example 2: low-grade mixed glioma
Layer 3, WHO grade: reflecting natural history; may be left out when uncertain or otherwise confusing
 Example 1: WHO grade III or IV (dependent on molecular information)
 Example 2: WHO grade II
Layer 4, molecular information: synoptic account of type of test(s) performed and the results obtained; may temporarily be filled with ‘pend-
ing’ as well or with ‘not done’ (preferably with a reason, e.g., ‘not considered necessary’, ‘not available’, ‘insufficient tissue for testing’)
 Example 1: IDH1-R132H + (IHC), PTEN deletion (FISH), 1p/19q codeletion (FISH)
 Example 2: IDH1-R132H + (IHC), p53 ++ (IHC), ATRX − (IHC)
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exact criteria to be used for grading and the significance of 
such grading within molecular subgroups is warranted [33]. 
A recent study of 558 WHO grade II and III diffuse glio-
mas revealed that mitotic index was significantly associ-
ated with outcome in IDH wild type but not in IDH mutant 
tumors [84].
Other challenges that need to be tackled are how to put 
pediatric oligodendrogliomas (known to lack 1p/19q code-
letions) in the taxonomy of oligodendroglial tumors and 
which platforms and cut-off levels are the most ideal to 
be used for demonstration of particular molecular aberra-
tions. The different platforms for detection of the relevant 
Fig. 5  Example of how ‘molecular reclassification’ may affect tumor 
grade. This tumor, previously diagnosed as GBM-O, WHO grade 
IV featured mostly cells resembling astrocytoma (a, c) and included 
necrosis (a) and microvascular proliferation (b). Cells resembling oli-
godendroglioma were seen only focally (d). The expression of IDH1-
R132H mutant protein suggested that this represents either a second-
ary glioblastoma or an anaplastic oligodendroglioma, whereas the 
PTEN deletion identified by FISH is more common in glioblastoma 
(f; centromere 10 probe in green and PTEN probe in orange). Given 
the combined deletions of chromosome 1p (g; 1p probe in orange 
and 1q probe in green) and 19q (19p probe in green and 19q probe 
in orange), however, this case would be reclassified as an anaplastic 
oligodendroglioma, WHO grade III based on the most current recom-
mendations
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markers have their own strengths and weaknesses [45, 
98]. Importantly, for recognition of the clinically relevant 
1p/19q codeletion, assays capable of demonstrating whole-
arm losses are preferable, in order to minimize the risk of 
false positives from incomplete 1p and 19q losses (Fig. 7).
In the more distant future, the therapeutic management 
of individual patients may be determined by their ‘cancer 
signature’ rather than by the traditional pathological diag-
nosis [22]. For instance, the presence of an IDH mutation 
may provide an opportunity to apply specific, IDH targeted 
treatment, no matter if the diagnosis was astrocytoma or 
(1p/19q codeleted) oligodendroglioma [15, 106]. Further-
more, now that diffuse gliomas are increasingly diagnosed 
based on presence or absence of specific molecular aber-
rations, one can imagine that some of these tumors may 
be diagnosed by non- or minimally invasive approaches. 
Several groups already reported that molecular subgroups 
of gliomas (e.g., IDH mutant gliomas) may be recognized 
as such by advanced magnetic resonance evaluation [28, 
30, 57]. Alternatively, ‘liquid biopsies’ may increasingly 
be used to detect particular markers in blood of glioma 
patients [9, 66]. It remains to be seen though if such non-
invasive methods will ultimately provide information that is 
detailed and robust enough to replace tissue-based morpho-
logical and molecular analysis. Moreover, since the benefits 
of near-total resection of diffuse gliomas have long been 
recognized, tissue may continue to be obtained in most 
cases even if a diagnosis may be made by other means.
In conclusion, after almost a century of a histopathologi-
cally based classification of CNS tumors, we are now expe-
riencing the transition towards an integrated morphological 
and molecular definition of diffuse gliomas, with in some 
situations the clinical relevance of the molecular findings 
overriding the relevance of the histopathological diagno-
sis. This integrated diagnostic approach allows for much 
more robust recognition of biologically different subgroups 
within the spectrum of diffuse gliomas, thereby facilitat-
ing tailored treatment for individual patients. The official 
updating process of the 4th edition of the WHO classifica-
tion of CNS tumors has just begun and ‘the jury is still out’ 
with regard to what exactly the definitions for subgroups of 
diffuse gliomas will look like.
It can be expected that in the updated WHO classifica-
tion (publication of which is scheduled early in 2016) dem-
onstration of (complete) 1p/19q codeletion will indeed be 
required for the diagnosis of ‘canonical oligodendroglioma’ 
and that the (poorly reproducible) diagnosis of mixed glio-
mas will largely disappear. Such a change will bring new 
challenges as well, e.g., regarding how criteria for grading 
within the molecular groups should be adapted, how pedi-
atric oligodendrogliomas should be defined, which plat-
forms and cut-off levels should ideally be used for molec-
ular diagnostics, and how to stay connected with centers/
countries where molecular testing is not available. Also, 
acknowledging that our knowledge on the molecular under-
pinnings of cancer will continue to rapidly expand, it may 
Fig. 6  Example where ‘molecular reclassification’ does not affect 
tumor grade. This previously diagnosed oligoastrocytoma, WHO 
grade II (a) with IDH1 R132H mutant protein (b) would now be 
reclassified as a diffuse astrocytoma, WHO grade II based on strong 
p53 expression (c correlating well albeit imperfectly with TP53 muta-
tion) and loss of ATRX expression (d note positive expression in non-
neoplastic nuclei serving as a positive internal control)
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Fig. 7  For unequivocal assessment of 1p/19q codeletion in oligodendro-
glial tumors, detection of whole-arm losses is key. In order to avoid detec-
tion of false-positive cases with partial 1p and/or 19q loss, ideally a test 
is used that allows for analysis of multiple loci along each chromosome 
arm. a Example of an oligodendroglioma of which formalin-fixed, par-
affin-embedded tissue was analyzed for 1p/19q status by multiplex liga-
tion-dependent probe amplification (MLPA). With this platform, probes 
for 15 loci on chromosome 1p and 8 loci on 19q are used to interrogate 
these chromosome arms for loss or gain [the rest of the probes (3 on 1q, 
2 on 19p, 15 on other chromosomes) serve as copy number references]. 
The test is performed in duplicate (hence the two lines) and demonstrates 
a clear loss for all 1p and 19q probes in this case (see [49] for technical 
details). b Massively parallel sequencing (MPS) allows for much more 
detailed analysis of copy number aberrations in the (tumor) genome. This 
is an example of a low-grade oligodendroglioma of which four different 
regions were separately analyzed. Interestingly, while complete losses of 
chromosome arms 1p (indicated by the arrow) and 19q (arrowhead) were 
uniformly present in the different regions, other copy number aberrations 
were only detected in some regions (most strikingly in area I, see region 
marked by red box). As the deletions for 1p and 19q loss in the different 
regions are at a similar level, this heterogeneity for copy number aberra-
tions of other chromosomes cannot simply be explained by a difference in 
percentage of tumor cells in the different areas and must be interpreted as 
intratumoral genetic heterogeneity. Image b is modified from [122]
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well be necessary to prepare for more frequent updates of 
tumor classifications than we have seen so far. A multidis-
ciplinary team-effort is needed to do derive the right bal-
ance between state-of-the-art science and clinical practical-
ity in this respect [74, 99].
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